{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:40:01Z","timestamp":1778535601910,"version":"3.51.4"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T00:00:00Z","timestamp":1397692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J cachexia sarcopenia muscle"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>IGF\u20101 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF\u20101 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF\u20101 on muscle mass is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated muscle mass at L3 in patients enrolled in a randomized phase II study of MK\u20100646 (M), a monoclonal antibody directed against the IGF\u20101 protein, in patients with metastatic pancreatic cancer (MPC). Two different doses of M were tested, 5 and 10\u00a0mg\/kg. We used the Slice\u2010o\u2010matic (ver 4.3) software to segregate CT images into muscle and fat components and measured muscle area (cm<jats:sup>2<\/jats:sup>) at baseline and after 2 and 4\u00a0months of treatment. Patients received either gemcitabine with erlotinib (G\u2009+\u2009E), G\u2009+\u2009E\u2009+\u2009M, or G\u2009+\u2009M. Differences between the groups were compared using <jats:italic>t<\/jats:italic> tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010three patients had both baseline and 2\u2010month imaging available for analysis. Of these, 42 received M with their chemo, and 11 had G\u2009+\u2009E only. After 2\u00a0months of treatment, both groups demonstrated decrease in muscle mass. G\u2009+\u2009E patients lost 5.6\u00a0% of muscle mass; M patients lost 9.1 and 8.6\u00a0% after treatment with 5 and 10\u00a0mg\/kg, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.53). Patients demonstrating a response lost less muscle (median 4.6\u00a0%) than those with stable disease (9.6\u00a0%) and progressive disease (8.9\u00a0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.14). Muscle retention from baseline to 2\u2010month imaging, defined as loss of &lt;6\u00a0cm<jats:sup>2<\/jats:sup> of muscle, correlated with better survival than those patients demonstrating a muscle loss (HR 0.51, <jats:italic>p<\/jats:italic>\u2009=\u20090.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MPC patients can be expected to lose muscle mass even while having clinical benefit (PR or SD) from chemotherapy. Muscle loss correlated with a risk of study drop\u2010out and death. There was a non\u2010significant trend toward greater muscle mass loss in patients on anti\u2010IGF\u20101R therapy. However, it is unclear if this loss translates into functional differences between patients.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s13539-014-0145-y","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T11:37:37Z","timestamp":1397648257000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?"],"prefix":"10.1002","volume":"5","author":[{"given":"David R.","family":"Fogelman","sequence":"first","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"},{"name":"Department of G.I. Medical Oncology U.T.\/M.D. Anderson Cancer Center  1515 Holcombe Blvd Unit 426 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Holmes","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Forrest Hills Hospital  Queens NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H. G.","family":"Katz","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M.","family":"Prado","sequence":"additional","affiliation":[{"name":"Florida State University  Tallahassee FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Lieffers","sequence":"additional","affiliation":[{"name":"School of Public Health Systems University of Waterloo  Waterloo ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Garg","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauri R.","family":"Varadhachary","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachna","family":"Shroff","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Garrett","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center  1515 Holcombe Drive 77030 Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0779"},{"key":"e_1_2_6_4_1","first-page":"5073","article-title":"An anti\u2010insulin\u2010like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation","volume":"63","author":"Maloney EK","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","unstructured":"Javle MM V.G. Shroff RT Bhosale P Overman MJ Weatherly J Wolff RA Abbruzzese JL Phase I\/II study of MK\u20100646 the humanized monoclonal IGF\u20101R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J Clin Oncol 2010.28: p. 4039.;","DOI":"10.1200\/jco.2010.28.15_suppl.4039"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003677-200201000-00004"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/84839"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.08.002"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1249\/00003677-199800260-00004"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.03.017"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00744.2004"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e328331124a"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1998.85.1.115"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1139\/H08-075"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1988.64.3.1038"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.060228"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1007%2Fs13539-014-0145-y","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/s13539-014-0145-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:00:57Z","timestamp":1700618457000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1007\/s13539-014-0145-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,17]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1007\/s13539-014-0145-y"],"URL":"https:\/\/doi.org\/10.1007\/s13539-014-0145-y","archive":["Portico"],"relation":{},"ISSN":["2190-5991","2190-6009"],"issn-type":[{"value":"2190-5991","type":"print"},{"value":"2190-6009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,17]]},"assertion":[{"value":"2013-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}